早期达到 isavuconazole 目标度使用增加的加载剂量在危急病患者与体外膜氧化
Stefan Hatzl1,2,3, Lisa Kriegl4, Florian Posch5
1Intensive Care Unit, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
在身体外膜氧化 (ECMO) 的重症患者中,将伊萨夫康纳的初始加载剂量增加到400毫克,可以迅速达到目标血度. 这种较高的负载剂量从一开始就确保有效的抗真菌水平,没有不良事件.
科学领域:
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
背景情况:
- 在体外膜氧化 (ECMO) 治疗的重症患者经常经历延迟达到标准加载剂量的目标伊萨武科纳度.
- 这种延迟可能会影响抗真菌治疗在这个脆弱人群中的有效性.
研究的目的:
- 评估加大伊萨武科纳的初始加载剂量对经过ECMO的重症患者的血度的影响.
- 为了确定更高的加载剂量是否可以更快地达到治疗药物水平.
主要方法:
- 一项涉及15名ECMO重症患者的研究.
- 在初始剂量后,对伊萨夫可纳的血度进行了连续测量.
- 根据中间分析和安全监测,第一个充满剂量从200毫克逐渐增加到300毫克,最后增加到400毫克.
主要成果:
- 与较低剂量相比,接受400毫克初始加载剂量的患者在前24小时内达到显著更高的伊萨武可纳度.
- 所有患者组在24小时后都达到可比的血度,不论是初始加载剂量.
- 没有度超过5mg/L,也没有观察到与伊萨武可纳相关的不良事件.
结论:
- 在重症ECMO患者中,400毫克的伊萨武科纳的加载剂量会导致立即的血中位度超过1毫克/升.
- 在初始400毫克剂量后,这些度始终保持在治疗值以上,这表明早期暴露有所改善.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
06:41Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
Published on: October 24, 2018
相关概念视频
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Acute Respiratory Failure-IV
Acute Respiratory Failure-III
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
